Drug Profile
Research programme: prostate cancer therapeutics - Sophia Bioscience
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Sophia Bioscience
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 10 Aug 2016 Preclinical trials in Prostate cancer in USA (unspecified route)